Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.

Gonzalez-Rodriguez, E.; Aubry-Rozier, B.; Stoll, D.; Lamy, O.

doi:10.1002/art.41016

Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.

Détails

Demande d'une copie

ID Serval

serval:BIB_F90DC7040A4D

Type

Article: article d'un périodique ou d'un magazine.

Sous-type

Lettre (letter): communication adressée à l'éditeur.

Collection

Publications

Institution

UNIL/CHUV

Titre

Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.

Périodique

Arthritis & rheumatology

Auteur⸱e⸱s

Gonzalez-Rodriguez E., Aubry-Rozier B., Stoll D., Lamy O.

ISSN

2326-5205 (Electronic)

ISSN-L

2326-5191

Statut éditorial

Publié

Date de publication

10/2019

Peer-reviewed

Oui

Volume

Numéro

Pages

1770-1771

Langue

anglais

Notes

Publication types: Letter ; Comment
Publication Status: ppublish

Résumé

We read with interest the Article by KG. Saag and colleagues (1). This 24-month randomised trial demonstrated the efficacy and safety of denosumab compared with risedronate. The discussion does not take into account three major concerns regarding denosumab discontinuation (DD) that could modify the conclusions. This article is protected by copyright. All rights reserved.

Mots-clé

Bone Density Conservation Agents, Denosumab, Diphosphonates, Double-Blind Method, Glucocorticoids, Humans, Osteoporosis, Risedronic Acid

OAI-PMH

oai:serval.unil.ch:BIB_F90DC7040A4D

DOI

10.1002/art.41016

Pubmed

31215777

Web of science

000484426600001

Création de la notice

24/06/2019 17:09